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Abstract
The gammaretroviruses xenotropic murine leukemia virus (MLV)-related virus (XMRV) and MLV have been reported to be
more prevalent in plasma and peripheral blood mononuclear cells of chronic fatigue syndrome (CFS) patients than in
healthy controls. Here, we report the complex analysis of whole blood and plasma samples from 58 CFS patients and 57
controls from Canada for the presence of XMRV/MLV nucleic acids, infectious virus, and XMRV/MLV-specific antibodies.
Multiple techniques were employed, including nested and qRT-PCR, cell culture, and immunoblotting. We found no
evidence of XMRV or MLV in humans and conclude that CFS is not associated with these gammaretroviruses.
Citation: Steffen I, Tyrrell DL, Stein E, Montalvo L, Lee T-H, et al. (2011) No Evidence for XMRV Nucleic Acids, Infectious Virus or Anti-XMRV Antibodies in Canadian
Patients with Chronic Fatigue Syndrome. PLoS ONE 6(11): e27870. doi:10.1371/journal.pone.0027870
Editor: K.T. Jeang, National Institute of Health, United States of America
Received October 12, 2011; Accepted October 26, 2011; Published November 17, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by the Canada Excellence Research Chair (M.H.) and the Li Ka Shing Institute of Virology. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: michael.houghton@ualberta.ca
Introduction
Chronic fatigue syndrome (CFS), also commonly referred to as
myalgic encephalomyelitis (ME), is a complex disorder with an
unknown etiology which is characterized by disabling physical and
mental fatigue and pain that lasts for at least 6 months and lacks
any obvious cause [1,2]. The sudden onset of symptoms and
underlying activation of inflammatory pathways suggest an
infectious agent as the triggering factor. Numerous viral and
non-viral pathogens have been investigated in the context of CFS
with as yet inconclusive results [1,2]. The xenotropic murine
leukemia virus (MLV)-related virus (XMRV) was initially
identified in human prostate cancer cells in 2006 [3]. It has since
been thought to be the only member of the gammaretrovirus
family known to infect humans and its possible role in the
development of prostate cancer has been widely discussed [4]. In
2009, Lombardi et al. reported the detection of XMRV in both
peripheral blood mononuclear cells (PBMC) and plasma of 67% of
a CFS patient cohort compared to 3.7% in healthy controls [5].
This study has gained a high level of attention and was thought to
mark a possible break-through in CFS research. Several studies
have since addressed the possible connection between XMRV
infection and CFS or prostate cancer, and the resulting evidence is
controversially discussed in the field [4]. While one study reported
the presence of other MLV-like sequences in CFS patients [6],
others identified mouse DNA, human cell lines or commercial
laboratory reagents to be a possible source of MLV contamination
[7]. Attempts to reproduce the initial findings in different CFS
patient groups world-wide and in parts of the initial cohort have
since failed [4,8,9]. Thus, more research is needed to resolve an
association of MLV-like viruses in humans. In this study we
performed an extensive analysis of whole blood and plasma
samples from two well-characterized Canadian CFS patient
cohorts and healthy controls utilizing multiple laboratory tech-
niques, including nested and qRT-PCR, cell culture, and
immunoblotting for the detection of XMRV/MLV nucleic acids,
infectious virus, and XMRV/MLV-specific antibodies.
Materials and Methods
Ethics statement
All study protocols were reviewed and approved by the Human
Research Ethics Boards of the University of Calgary and the
University of Alberta and all study participants provided written
informed consent. Laboratory testing of the samples was
performed anonymously and blinded.
Cohorts
All patients and controls examined in this study were part of
cohorts from either Calgary or Edmonton, recruited in 2010 and
2011, respectively. All participants completed the De Paul
Questionnaire [10] to gather demographic data and to elicit the
Canadian Consensus Criteria (CCC) for ME/CFS as established
by Carruthers et al. [1]. Moreover, all participants were screened
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meet the CCC and one participant did not meet Fukuda criteria,
but all three were included on clinical grounds. The remainder of
the CFS group met both the CCC and the Fukuda criteria.
Healthy controls who showed more than one symptom of ME/
CFS at moderate or greater severity were excluded. The CFS
group (58 individuals) had a mean age of 48.9610.1 years and
90% were female, compared to the healthy control group (57
individuals) with a mean age of 47.6610.6 years and 89% female,
reflecting the higher prevalence of the disease amongst women. A
documented infectious onset could be reported by 59% of the CFS
patients. Of the CFS patients, 93% have been sick for more than 2
years and 3% have been sick for 1–2 years, while 5% showed
symptoms since childhood or adolescence.
Nested RT-PCR
For detection of XMRV/MLV sequences by nested PCR, RNA
was extracted from 0.5 ml plasma using the QIAamp Ultrasens
Virus Kit (Qiagen). The isolated RNA was immediately subjected
to reverse transcription employing the Superscript III First-Strand
Synthesis System for RT-PCR (Invitrogen). Culture supernatant
from the XMRV-producing prostate cancer cell line 22Rv1 was
used at a 10
25 dilution as a positive control for RNA isolation. For
amplification of XMRV/MLV gag sequences, 5 ml of the
transcribed cDNA were used for the first round of amplification
with primers 419F (59-ATCAGTTAACCTACCCGAGTCG-
GAC-39) and 1154R (59-GCCGCCTCTTCTTCATTGTTC-
TC-39) [5] and HotStart-IT FideliTaq Master Mix (USB) with
the recommended component volumes. The amplification was
initiated by incubation for 4 min at 94uC, followed by 40 cycles of
1 min at 94uC, 1 min at 57uC and 1 min at 72uC, and a final
incubation for 10 min at 72uC. Nested PCR was performed under
the same conditions for 45 amplification cycles with 5 ml of the first
round PCR product and two different primer pairs, Gag-I-F (59-
TCTCGAGATCATGGGACAGA-39) and Gag-I-R (59-AGA-
GGGTAAGGGCAGGGTAA-39) or NP116 (59-CATGGGACA-
GACCGTAACTACC-39) and NP117 (59-GCAGATCGGGAC-
GGAGGTTG-39), both of which have been shown to detect both
XMRV and MLV sequences [6]. To determine the assay
sensitivity, serial dilutions of a cloned fragment of XMRV gag
[9] ranging from 1 to 100 copies/ ml were included in each PCR.
The resulting PCR amplification products (730 bp for first round
PCR and 413 bp or 380 bp for second round PCR, respectively)
were analyzed by electrophoresis in 1.5% agarose gels. Any bands
of approximately the correct size were excised and subjected to
sequencing in order to determine homology to MLVs.
qRT-PCR
For qRT-PCR analysis, RNA was extracted from 100 mlo f
either whole blood or plasma using the Qiagen Viral RNA Mini
Kit. The isolated RNA was subjected to reverse transcription by
murine leukemia virus (MuLV) reverse transcriptase (Roche). The
resulting cDNA was amplified in a real-time PCR reaction and
quantified in a Roche LightCycler 480. Two different primer and
probe sets were used for amplification of two distinct regions of the
XMRV genome: primers XMRV-F2 59-AACCTGATGGCA-
GATCAAGC-39 and XMRV-R2 59-CCCAGTTCCCGTAGT-
CTTTTGAG-39 and probe FAM-AGTTCTAGAAACCTCTA-
CACTC-BHQ1 for amplification of the XMRV integrase gene
[11], and WPI primers Q445F 59-GGACTTTTTGGAGTG-
GCTTTGTT-39 and Q528R 59- GCGTAAAACCGAAAG-
CAAAAAT-39 and probe FAM-ACAGAGACACTTCCCG-
CCCCCG-BHQ1 for amplification of the XMRV-specific gag
leader sequence [12] with FastStart Taq polymerase (Roche) in 45
amplification cycles of 95uC and 60uC for 30 sec each. Serial
dilutions of a cloned fragment of XMRV gag [9] were used to
produce standard curves (Fig. 1C). The sensitivity of the qRT-
PCR assay was below 10
3 copies/ml plasma or whole blood.
Virus culture
DERSE (Detectors of Exogenous Retroviral Sequence Ele-
ments) indicator cells were developed at the National Cancer
Institute by stable transfection of pBabe.iGFP-puro into LNCaP
cells. pBabe.iGFP-puro is an MLV vector encoding puromycin
resistance and a CMV promoter driven GFP reporter gene which
is interrupted by an intron placed in sense direction relative of the
vector and transcribed antisense to the vector mRNA. The intron
interrupted GFP gene is only expressed after mobilization by an
infecting gammaretrovirus for a second round of infection. After
screening clonal cell populations, the most sensitive clones were
chosen and designated as DERSE.Li-G cells. To test for the
presence of infectious MLVs in patient plasma, DERSE.Li-G cells
were inoculated with CFS patient plasma or control plasma. Cells
were seeded 72 hours before infection with 3610
4 cells/ml in 6-
well plates. For spinoculation, the medium was removed and
300 ml fresh medium and 50 ml plasma were added per well. The
plates were centrifuged at 1,200 rpm for 1 hour and 0.5 ml fresh
medium was added. The inoculum was removed the next day and
the cells were cultured in 2 ml fresh medium and monitored for
GFP expression every 3 to 4 days for a total period of 3 weeks. As a
positive control, culture supernatant from the 22Rv1 cell line
(containing roughly 10
9 copies/ml as determined from the average
of seven individual qPCR assays, data not shown) was used as an
inoculum at 10
24, and 10
26 dilution, respectively.
Serology
Western blot (WB) analysis was performed to detect anti-
XMRV/MLV antibodies in CFS patient sera and healthy
controls. Purified XMRV antigen from XMRV-infected DU145
prostate cells (C7) was denatured with SDS-PAGE sample buffer
at 95uC for 10 min and analyzed by immunoblotting as previously
described [9]. Seroreactivity was defined by reactivity to viral Env
and/or Gag proteins of the expected size as seen in the positive
control antisera (Fig. 2B).
Results
Whereas XMRV gag sequences were readily detectable in
diluted 22Rv1 cell supernatants, XMRV and MLV were not
detected in any of the patient plasma samples (Fig. 1A and B). The
detection limit of the nested PCR assay was below 1 copy/ ml
isolated RNA or 5 copies/reaction as determined by the detection
of known amounts of XMRV plasmid DNA (Fig. 1B). The
sensitivity of the qRT-PCR assay was below 10
3 copies/ml plasma
or whole blood. Regardless of whether whole blood or plasma was
tested, all human samples were negative for detectable amounts of
XMRV nucleic acid (data not shown).
DERSE.Li-G cells inoculated with 22Rv1 supernatants showed
a concentration-dependent GFP expression on day 7 and spread of
the virus on day 21. GFP expression was not observed in any of the
DERSE.Li-G cells inoculated with patient plasma (typical example
shown in Fig. 2A).
Seroreactivity was defined by Western blot reactivity to viral
Env and/or Gag proteins of the expected size as seen in the
positive control antisera (Fig. 2B). None of the 115 human plasma
reacted with the purified XMRV antigen indicating an absence of
antibodies to XMRV/MLV in the samples (typical example
shown in Fig. 2B). Increased background noise as observed for one
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expression of DERSE.Li-G cells 7 days (upper panels) or 21 days (lower panels) after spinoculation with two different dilutions of 22Rv1 cell culture
supernatants (10
24 and 10
26 dilution) or patient plasma. No GFP expression could be observed in any of the cells inoculated with human plasma. B)
Immunoblotting of C7-purified XMRV antigen with patient plasma for detection of anti-XMRV/MLV antibodies. Representative WB results for CFS
patients and healthy controls. Lane 1, anti-Friend MuLV whole virus, goat polyclonal antisera; lane 2, anti-Rauscher MuLV envelope, goat polyclonal
antisera; lane 3, XMRV negative blood donor plasma. Locations of reactivity to specific viral proteins are indicated; Env (gp69/71), envelope; TM
(p15E), transmembrane; MA (p15), matrix; Gag (pr68); CA (p30), capsid.
doi:10.1371/journal.pone.0027870.g002
Figure 1. Failure of detection of XMRV nucleic acids in plasma and whole blood of CFS patients and healthy controls. A) First round
PCR products of a representative number of RNA samples isolated from patient plasma using primers 419F and 1154R. A 10
25 dilution of 22Rv1 cell
culture supernatant and three known concentrations of XMRV plasmid DNA were included as controls. B) Second round amplification products of
nested PCR using primers Gag-I-F and Gag-I-R of samples shown in A). Identical results were obtained with primers NP116 and NP117 (see text, data
not shown). The detection limit was below 1 copy/ ml isolated RNA or 5 copies/reaction. C) Results of qRT-PCR for XMRV plasmid control in serial
dilutions ranging from 10
6 to 10
2 copies/ml as well as negative controls for both primer pairs used, F2/R2 (upper panel) and WPI (lower panel). All
patient plasma and whole blood samples were found to be negative after a total of 45 amplification cycles (data not shown).
doi:10.1371/journal.pone.0027870.g001
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the presence of cross-reactive epitopes.
Discussion
In summary, we were unable to detect any evidence of XMRV
or MLV infection in any of the 115 examined study participants,
regardless of whether they were suffering from CFS or represented
healthy controls. The 58 CFS patients enrolled in this study were
carefully selected according to the Canadian Consensus Criteria
for ME/CFS. Positively screened participants were only included
if they showed symptoms in at least two categories of autonomous,
neuroendocrine, and immune manifestations. The sensitivity of
our assays reached copy numbers lower than 120 copies/ml of
plasma for the detection of viral nucleic acids, and 10
3 copies/ml
of plasma for the presence of infectious particles. While it is
possible that XMRV and MLV are not predominantly blood-
borne viruses and as such exist below the detection limit of most
assays in plasma and whole blood, we believe that the assays used
in this study are equally sensitive to those reported in previous
positive studies. Moreover, our broad study design and the use of
degenerate primers with specificity for highly conserved sequences
in different MLV-like viruses and XMRV would have allowed us
to identify nucleic acids, infectious particles, and antibodies for a
number of related murine retroviruses. However, we could not
detect any other murine retroviruses in any of our specimens,
unlike the finding of MLV-like sequences reported by Lo et al. [6].
CFS patient cohorts have been tested for the presence of
XMRV in the United States, Netherlands, Germany, China, and
United Kingdom among others [4]. Being more aware of the
possible risk of contaminants in commonly used laboratory
reagents [13], none of these studies were able to reproduce the
initial findings. Moreover, repeated testing of CFS patients
previously reported to be infected with XMRV in the initial study
performed by Lombardi et al. failed to detect any signs of XMRV
infection in these patients [8]. On the contrary, it is now becoming
increasingly clear that XMRV found in the prostate cancer cell
line 22Rv1 originated from recombination of two MLVs present
in the mouse strains used for passaging of the initial prostate
cancer xenograft [14]. The fact that the viral sequences initially
identified in prostate and CFS samples are virtually identical to
those found in 22Rv1 cells [15] suggests that the assumed
association of XMRV with human diseases is due to sporadic
laboratory contamination. Moreover, differential handling of
patient samples compared to controls can introduce bias and
was therefore carefully avoided in this study. Two independent
studies could show that handling of human samples in laboratory
environments with abundant endogenous MLV proviruses can
lead to the false detection of XMRV/MLV-like sequences due to
contamination as proven by PCR detection of the highly abundant
intracisternal A-type particle (IAP) long terminal repeat in the
same samples [16,17]. In the light of the accumulating evidence
for the artefactual origin of XMRV and the high burden of MLV-
like DNA contamination the initially reported connection of
XMRV and prostate cancer is now being ruled out as well [18].
Thus, although XMRV was found to infect and replicate in a
variety of human cells, natural XMRV/MLV infection of humans
has not yet been reproduced and is believed to be a false-positive
result from mouse DNA and/or MLV-contaminated PCR
reagents [13]. This study examines a possible association of
XMRV and chronic fatigue in a Canadian patient cohort and is
consistent with a number of recently published reports declaring
no evidence for the presence of MLV-like viruses in any human
subjects. In conclusion, while this study and others fail to support
an association between XMRV and CFS, they highlight the
urgent need for further research into the root causes of CFS.
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